Alerts will be sent to your verified email
Verify Email
PGHL
|
Procter&Gamble Healt
|
FDC
|
Marksans Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Domestic Sales Growth - YoY
|
54.51 % | 5.7 % | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
30.46 % | 13.66 % | 18.16 % |
|
5yr average Equity Multiplier
|
2.99 | 1.57 | 1.35 |
|
5yr Average Asset Turnover Ratio
|
0.57 | 0.54 | 0.99 |
|
5yr Avg Net Profit Margin
|
17.93 % | 16.24 % | 13.73 % |
|
Price to Book
|
13.65 | 3.05 | 4.5 |
|
P/E
|
35.21 | 25.43 | 27.84 |
|
5yr Avg Cash Conversion Cycle
|
-158.56 Days | -14.0 Days | 69.54 Days |
|
Inventory Days
|
36.98 Days | 59.23 Days | 87.55 Days |
|
Days Receivable
|
29.14 Days | 21.91 Days | 69.35 Days |
|
Days Payable
|
177.2 Days | 86.54 Days | 84.4 Days |
|
5yr Average Interest Coverage Ratio
|
337.3 | 93.3 | 32.98 |
|
5yr Avg ROCE
|
19.93 % | 14.95 % | 23.15 % |
|
5yr Avg Operating Profit Margin
|
24.91 % | 18.97 % | 19.67 % |
|
5 yr average Debt to Equity
|
0.0 | 0.0 | 0.02 |
|
5yr CAGR Net Profit
|
-4.58 % | 4.94 % | 21.8 % |
|
5yr Average Return on Assets
|
10.24 % | 8.73 % | 13.43 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
51.82 % | 69.66 % | 43.87 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.3 % | -4.38 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
4.1 % | 0.49 % | 2.91 % |
|
Procter&Gamble Healt
|
FDC
|
Marksans Pharma
|
|
|---|---|---|---|
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Drug Delivery Break-Up
|
Drug Delivery Break-Up
|
-
|
-
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|